Synonym
AM-36; AM 36; AM36; UNII-08OBY024NY; SCHEMBL12311270; CNSB 002; CNSB-002; CNSB002;
IUPAC/Chemical Name
2,6-ditert-butyl-4-[[4-[2-(4-chlorophenyl)-2-hydroxyethyl]piperazin-1-yl]methyl]phenol
InChi Key
ZGSFWANJADAZQC-UHFFFAOYSA-N
InChi Code
InChI=1S/C27H39ClN2O2/c1-26(2,3)22-15-19(16-23(25(22)32)27(4,5)6)17-29-11-13-30(14-12-29)18-24(31)20-7-9-21(28)10-8-20/h7-10,15-16,24,31-32H,11-14,17-18H2,1-6H3
SMILES Code
CC(C)(C)C1=CC(=CC(=C1O)C(C)(C)C)CN2CCN(CC2)CC(C3=CC=C(C=C3)Cl)O
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO, not in water
Shelf Life
>2 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
Preparing Stock Solutions
The following data is based on the
product
molecular weight
459.06
Batch specific molecular weights may vary
from batch to batch
due to the degree of hydration, which will
affect the solvent
volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass |
1 mg |
5 mg |
10 mg |
| 1 mM |
1.15 mL |
5.76 mL |
11.51 mL |
| 5 mM |
0.23 mL |
1.15 mL |
2.3 mL |
| 10 mM |
0.12 mL |
0.58 mL |
1.15 mL |
| 50 mM |
0.02 mL |
0.12 mL |
0.23 mL |
1: Nicolazzo JA, Nguyen TT, Katneni K, Steuten JA, Smith G, Jarrott B, Callaway JK, Charman SA. Pharmacokinetics and brain uptake of AM-36, a novel neuroprotective agent, following intravenous administration to rats. J Pharm Pharmacol. 2008 Feb;60(2):171-8. doi: 10.1211/jpp.60.2.0005. PubMed PMID: 18237464.
2: Weston RM, Jarrott B, Ishizuka Y, Callaway JK. AM-36 modulates the neutrophil inflammatory response and reduces breakdown of the blood brain barrier after endothelin-1 induced focal brain ischaemia. Br J Pharmacol. 2006 Nov;149(6):712-23. Epub 2006 Oct 3. PubMed PMID: 17016500; PubMed Central PMCID: PMC2014659.
3: Callaway JK, Castillo-Melendez M, Giardina SF, Krstew EK, Beart PM, Jarrott B. Sodium channel blocking activity of AM-36 and sipatrigine (BW619C89): in vitro and in vivo evidence. Neuropharmacology. 2004 Jul;47(1):146-55. PubMed PMID: 15165842.
4: Callaway JK, Lawrence AJ, Jarrott B. AM-36, a novel neuroprotective agent, profoundly reduces reactive oxygen species formation and dopamine release in the striatum of conscious rats after endothelin-1-induced middle cerebral artery occlusion. Neuropharmacology. 2003 May;44(6):787-800. PubMed PMID: 12681377.
5: Callaway JK. Investigation of AM-36: a novel neuroprotective agent. Clin Exp Pharmacol Physiol. 2001 Nov;28(11):913-8. Review. PubMed PMID: 11703395.
6: Callaway JK, Beart PM, Jarrott B, Giardina SF. Incorporation of sodium channel blocking and free radical scavenging activities into a single drug, AM-36, results in profound inhibition of neuronal apoptosis. Br J Pharmacol. 2001 Apr;132(8):1691-8. PubMed PMID: 11309240; PubMed Central PMCID: PMC1572735.
7: Callaway JK, Knight MJ, Watkins DJ, Beart PM, Jarrott B. Delayed treatment with AM-36, a novel neuroprotective agent, reduces neuronal damage after endothelin-1-induced middle cerebral artery occlusion in conscious rats. Stroke. 1999 Dec;30(12):2704-12; discussion 2712. PubMed PMID: 10583001.
